2015-2019年我国接受抗病毒治疗成年HIV/AIDS患者病死率分析

Fatality among adult people living with HIV/AIDS who received antiretroviral therapy during 2015-2019 in China

目的分析2015-2019年期间我国接受ART成年HIV/AIDS患者病死率变化情况。方法采用连续横断面研究方法,以自然年为单位,描述性分析全国2015-2019年历年接受ART成年HIV/AIDS患者主要特征及粗病死率,并以2015年年龄构成为标准,计算历年年龄标化病死率。结果2015-2019年历年纳入分析的接受ART成年HIV/AIDS患者人数分别为416360例、515524例、623995例、755837例和885037例,其中≥50岁者占比依次为28.04%、29.48%、31.04%、33.23%和36.00%;历年接受ART成年HIV/AIDS患者中死亡人数分别为9920例、11784例、12880例、16876例和19961例,粗病死率依次为2.38%、2.29%、2.06%、2.23%和2.26%;2015-2019年年龄标化病死率依次为2.38%、2.24%、1.97%、2.06%和1.95%。结论2015-2019年期间,我国接受ART成年HIV/AIDS患者中≥50岁者占比逐年增加,死亡人数有所增长,粗病死率和年龄标化病死率均趋于平稳。

Objective To analyze the fatality's major characteristics among adult people living with HIV/AIDS who received antiretroviral therapy(ART)during 2015-2019 in China.Methods We conducted a consecutive cross-sectional analysis in this study.The main characteristics of the eligible adult people living with HIV/AIDS who received ART selected from the National Treatment Database and the crude fatality during 2015-2019 were analyzed.We calculated ageadjusted fatality with a standardization process,taking the age proportion in 2015 as the standard.Results During 2015-2019,there were 416360,515524,623995,755837 and 885037 eligible adult people living with HIV/AIDS received ART included in our analysis,respectively.From 2015,the proportion of≥50 years old HIV/AIDS increased year by year with the results of 28.04%,29.48%,31.04%,33.23%and 36.00%.The death cases of the eligible adult people living with HIV/AIDS who received ART in our analysis were 9920,11784,12880,16876 and 19961,with the crude fatalities were 2.38%,2.29%,2.06%,2.23%and 2.26%,respectively.The age-adjusted fatalities were 2.38%,2.24%,1.97%,2.06%and 1.95%,respectively.Conclusions The proportion of≥50 years old among eligible adult people living with HIV/AIDS who received ART in our analysis has gradually increased year by year.The numbers of death cases also increase during 2015-2019.The crude and age-adjusted fatalities of 2015-2019 have remained relatively stable among adult people living with HIV/AIDS who received ART in China.